<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
<th>Track</th>
<th>Presentation Title</th>
<th>Speaker</th>
</tr>
</thead>
</table>
| 11-Nov | 6:00-7:00 AM   | Clinical    | A Comprehensive Toxicology Screening Solution Targeted to Individual Needs           | Ping Wang, PhD, DABCC, FACB
Director of Clinical Chemistry, Houston Methodist Hospital, Associate Professor, Pathology and Laboratory Medicine, Weill Cornell Medical College |
| 11-Nov | 6:00-7:00 AM   | Clinical    | Clinical next-generation sequencing for precision cancer therapeutics                | Christina (Tina) Lockwood, PhD, DABCC, FACB
Associate Director, Genetics and Solid Tumor Diagnostics Laboratory, Assistant Professor, Department of Laboratory Medicine, University of Washington |
| 11-Nov | 6:00-7:00 AM   | Industry    | Next-generation sequencing for BRCA1 and BRCA2 mutation testing                     | Raed Samara, PhD
Senior Global Product Manager, QIAGEN                                                   |
| 11-Nov | 7:30-8:30 AM   | Industry    | Keynote: Evolution of Standardization in Laboratory Medicine                        | Linda Thienpont, PhD, PHARM, Clinical Chemist
Professor of Analytical Chemistry, Statistics and Quality Control, Method
Development and Validation; Director of the Laboratory for Analytical Chemistry
ID-MS Reference Laboratory, Universit                                                  |
| 11-Nov | 9:00-10:00 AM  | FDA regulation of Laboratory Developed Tests | Keynote: FDA’s Proposed Framework for Regulatory Oversight of Laboratory Developed Tests | Katherine (Katie) Serrano
Deputy Director, Division of Chemistry and Toxicology Devices, Office of
In Vitro Diagnostics and Radiological Health, Food and Drug Administration Center for Devices and Radiological Health |
| 11-Nov | 10:30-11:30 AM | Industry    | Agilent StreamSelect LC/MS System: Future solutions for the high throughput lab     | Kevin McCann, BS
Application Scientist, Agilent Technologies                                               |
| 11-Nov | 10:30-11:30 AM | New lipid lowering guidelines-helpful or harmful? | Reliability of LDL cholesterol: How low can we go and when are we fooling ourselves? | Jeffrey Meeusen, Ph.D., DABCC
Co-Director, Cardiovascular Laboratory Medicine, Mayo Clinic                                |
| 11-Nov | 10:30-11:30 AM | Clinical    | Role of LC/MS/MS spectrometry in diagnosis of various endocrine disorders          | Ravinder Singh, PhD
Director, Endocrine Laboratory, Mayo Clinic                                              |
| 11-Nov | 12:00-1:00 PM  | New lipid lowering guidelines-helpful or harmful? | Cholesterol Treatment Guidelines: Controversies and use in clinical practice         | Michael Rocco, MD
Medical Director of Cardiac Rehabilitation and Stress Testing, Staff
Cardiologist, Cleveland Clinic                                                           |
| 11-Nov | 12:00-1:00 PM  | Industry    | DNASTAR Software for Accurate Variant Detection and Validation in Targeted Gene Panel Data Sets | Matthew Keyser, MS
Senior Manager, NGS Applications, DNASTAR                                               |
<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
</table>
| 11-Nov | 1:30-2:30 PM  | Industry                 | Improving Diagnostic Testing and Interpretation of Chronic Kidney Disease (CKD) | Kevin J Martin, MD, MB, BCh, FASN  
Professor of Internal Medicine, Director of the Division of Nephrology,  
Saint Louis University School of Medicine  
Stuart M Sprague, DO, FACP, FASN, FNKF  
Chief of the Division of Nephrology and Hypertension, and Director of Nephrology Research at NorthShore University HealthSystem and Clinical Professor of Medicine at the University of Chicago |
| 11-Nov | 1:30-2:30 PM  | FDA regulation of Laboratory Developed Tests | Why to validate diagnostic tests?                                      | Wieslaw Furmaga, MD  
Associate Professor, University of Texas Health Science Center at San Antonio |
| 11-Nov | 3:00-4:00 PM  | FDA regulation of Laboratory Developed Tests | Proposed Rule for the Medicare Clinical Diagnostic Laboratory Test Payment System | Jerry Stringham, MBA  
President, Medical Technology Partners |
| 12-Nov | 6:00-7:00 AM  | Laboratory Test Utilization | Laboratory Medicine: What should we be measuring?                    | Brian R Jackson  
Associate Professor of Pathology (Clinical), Medical Director of Informatics, ARUP Laboratories, University of Utah, Department of Pathology |
| 12-Nov | 7:30-8:30 AM  | Clinical Diagnostics     | Keynote: Reconceptualizing Genital Herpes Diagnosis and Management     | Edward Watson Hook, III, MD  
Professor of Medicine/Epidemiology/Microbiology, Director, Division of Infectious Diseases, The University of Alabama at Birmingham,  
Department of Medicine, Division of Infectious Diseases |
| 12-Nov | 9:00-10:00 AM | Industry                 | Introducing an ancestrally diverse whole genome data set for select cohort and control research applications | Benjamin D Solomon, MD  
Chief, Division of Medical Genomics, Inova Translational Medicine Institute, Associate Professor, Virginia Commonwealth University School of Medicine |
| 12-Nov | 9:00-10:00 AM | Industry                 | Use of a CD200R Inhibitor to Overcome Central Nervous System Tumor Induced Immunosuppression | Michael R Olin  
Assistant Professor, Department of Pediatrics, Division of Hematology/Oncology, University of Minnesota |
| 12-Nov | 10:30-11:30 AM| Industry                 | Graves' Disease Assessment: Current Trends in Laboratory Testing      | Damien Gruson, PhD  
Professor, Associated Laboratory Director, Saint-Luc University Hospital, Brussels, Belgium |
| 12-Nov | 10:30-11:30 AM| Laboratory Test Utilization | Pharmacogenetics in the Clinical Laboratory: Opportunities and Challenges | Allison Chambliss, PhD  
Clinical Chemistry Fellow, Department of Pathology, Johns Hopkins University School of Medicine |
| 12-Nov | 10:30-11:30 AM| Clinical Genomics        | Validation of Mass Spec Analytical Platforms and Proteomic Biomarkers: FDA perspective | Doug Jeffery, PhD  
Scientific Reviewer, Food and Drug Administration Center for Devices and Radiological Health |
<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
<th>Session</th>
<th>Topic</th>
<th>Speakers</th>
</tr>
</thead>
</table>
| 12-Nov | 12:00-1:00PM | Laboratory Test Utilization         | Keynote: Optimizing the use of laboratory testing services to improve patient diagnosis | Michael Laposata, MD, PhD
Professor and Chairman, Department of Pathology, University of Texas Medical Branch-Galveston
Julie R Taylor, PhD, MS
Project Lead for Clinical Laboratory Integration into Healthcare Collaborative CLIHC, Division of Laboratory Science and StandardsLSPPPO, Centers for Disease Control and Prevention (CDC) |
| 12-Nov | 1:30-2:30PM  | Clinical Diagnostics                | Genomics in Public Health Microbiology     | Ben Howden, PhD
Professor, Head of Laboratory, Microbiology and Immunology, Director, Microbiological Diagnostic Unit, University of Melbourne |
| 12-Nov | 1:30-2:30PM  | Industry                            | NGS in clinical research                   | Jennifer Fostel, MS
Senior Global Product Manager, NGS, Qiagen                                |
| 12-Nov | 1:30-2:30PM  | Laboratory Test Utilization         | Opportunities to simplify clinical lipid assessment | Howard Morris, PhD, FAACB, FFSc(RCPA)
Professor of Endocrine Bone Research Laboratory, Univ of South Australia
David R Sullivan, MBBS, FRACP, FRCPA
Clinical Associate Professor, Dept of Biochemistry, Royal Prince Alfred Hospital |